Top Buy Stocks
Sign In
Invest in CDXS
$2.23
-0.0200 (-0.89%)
At Close: Jun 13, 2025
Presentations by leading siRNA CDMOs, Bachem, Nitto Avecia, and ST Pharm, highlight performance and transferability of Codexis double-stranded RNA ligases
Codexis to Participate in Jefferies Global Healthcare Conference
04:05pm, Wednesday, 21'st May 2025
REDWOOD CITY, Calif., May 21, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced t
Codexis, Inc. (CDXS) Q1 2025 Earnings Call Transcript
06:50pm, Wednesday, 14'th May 2025
Codexis, Inc. (NASDAQ:CDXS ) Q1 2025 Earnings Conference Call May 14, 2025 4:30 PM ET Company Participants Carrie McKim - Director of Investor Relations Stephen Dilly - President and Chief Executive O
Codexis (CDXS) Reports Q1 Loss, Misses Revenue Estimates
06:40pm, Wednesday, 14'th May 2025
Codexis (CDXS) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.20. This compares to loss of $0.16 per share a year ago.
Codexis Reports First Quarter 2025 Financial Results
04:05pm, Wednesday, 14'th May 2025
Secured first revenue-generating contract for ECO Synthesis™ manufacturing services Company reiterates full-year financial guidance Six presentations to feature the ECO Synthesis platform at upcomin
Codexis Announces Six Presentations Featuring the ECO Synthesis Platform at TIDES USA Annual Meeting
07:00am, Wednesday, 07'th May 2025
Codexis to showcase data that demonstrate the scalability and reproducibility of its enzymatic siRNA manufacturing processes
Codexis to Report First Quarter 2025 Financial Results on May 14
04:05pm, Wednesday, 30'th Apr 2025
REDWOOD CITY, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced
Codexis (CDXS) Expected to Beat Earnings Estimates: Should You Buy?
11:09am, Thursday, 24'th Apr 2025
Codexis (CDXS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Codexis Announces Byron Dorgan to Retire from Board of Directors
05:00pm, Wednesday, 09'th Apr 2025
REDWOOD CITY, Calif., April 09, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced
Codexis Announces New Employment Inducement Grants
04:05pm, Friday, 07'th Mar 2025
REDWOOD CITY, Calif., March 07, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced
Codexis, Inc. (CDXS) Q4 2024 Earnings Call Transcript
10:20pm, Thursday, 27'th Feb 2025
Codexis, Inc. (NASDAQ:CDXS ) Q4 2024 Earnings Conference Call February 27, 2025 4:30 PM ET Company Participants Carrie McKim - Director of Investor Relations Stephen Dilly - President and Chief Execut
Codexis (CDXS) Reports Q4 Loss, Misses Revenue Estimates
07:35pm, Thursday, 27'th Feb 2025
Codexis (CDXS) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.02. This compares to earnings of $0.02 per share a year ago.
Codexis Announces New Employment Inducement Grants
05:15pm, Friday, 14'th Feb 2025
REDWOOD CITY, Calif., Feb. 14, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced t
Codexis to Report Fourth Quarter and Fiscal Year 2024 Financial Results on February 27th
04:05pm, Thursday, 13'th Feb 2025
REDWOOD CITY, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced t
Codexis Appoints Arthur Levin, PhD, to Strategic Advisory Board
04:05pm, Thursday, 06'th Feb 2025
REDWOOD CITY, Calif., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced t
